Last updated: March 1, 2026
What is the scope of JP6798400?
Patent JP6798400 protects a pharmaceutical compound with specific structural features. The patent covers methods of use, formulations, and manufacturing processes related to the compound. It primarily targets the treatment of a disease or condition by administering the compound.
The patent encompasses:
- The chemical entity as a novel compound, including its salts, stereoisomers, and derivatives.
- Methods of treatment involving the administration of the compound for specific indications.
- Pharmaceutical formulations that contain the compound for oral, injectable, or topical use.
- Manufacturing processes that produce the compound efficiently and with defined purity.
This broad scope aims to establish exclusivity over the compound's therapeutic application and formulations.
What are the main claims of JP6798400?
The patent contains multiple claims, with the core claims focused on the chemical structure and its use.
Independent claims:
- Claim 1: A chemical compound characterized by a specific core structure, with defined substituents and stereochemistry, including salts and stereoisomers.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1, combined with a pharmaceutically acceptable carrier.
- Claim 3: A method of treating a disease by administering an effective amount of the compound to a subject.
Dependent claims:
- Claims that specify particular salts, such as hydrochloride or sulfate.
- Claims defining specific formulations, like tablets or injections.
- Claims covering methods of synthesis for the compound.
The claims aim to cover both the compound itself and its therapeutic applications, as well as specific formulations and synthesis methods, providing a multi-tiered patent barrier.
How does the patent landscape look in Japan for similar compounds?
The patent landscape surrounding JP6798400 is characterized by several key aspects:
| Aspect |
Details |
| Overlapping patents |
Other Japanese patents cover chemical scaffolds similar to JP6798400, notably multiple filings by companies in pharmaceutical areas targeting similar indications. These include patents on related heterocyclic compounds and methods of use. |
| International filings |
Many of the core compounds are also subject to parallel patent applications under the Patent Cooperation Treaty (PCT) and filings in major jurisdictions like the US (e.g., USPTO) and Europe (EPO). These filings often claim broad chemical classes and therapeutic indications. |
| Expiry considerations |
The patent's filing date is crucial for calculating its expiration, typically 20 years from the earliest priority date. The earliest priority date is a key factor in assessable freedom-to-operate. |
| Major Players |
Patents |
Jurisdictions |
Focus Areas |
| Company A |
Several filings on heterocyclic compounds targeting cancer |
Japan, US, Europe |
Chemical compound and therapy broad claims |
| Company B |
Patents focusing on kinase inhibitors related to JP6798400 |
Japan, US |
Synthesis methods, salts, specific indications |
The patent landscape remains active, with patent filings often seeking to block generic challenges and extending coverage through various claims and jurisdictions.
What are the potential patent challenges for JP6798400?
- Novelty and inventive step: Prior art references in chemical and pharmaceutical patents could challenge novelty if similar structures or methods are disclosed.
- Scope examination: Broad claims might face restrictions or require narrowing if prior art reveals similar compounds or uses.
- Patent term and validity: The patent's enforceability depends on maintenance fees and ongoing legal validity, especially if prior art emerges or common general knowledge shifts.
What strategic considerations surround JP6798400?
- Patent life management: Supplementary patents on formulations or synthesis methods can extend competitive protection.
- Filing strategy: Parallel strategic patent filings in key markets (US, Europe, China) optimize global exclusivity.
- Litigation risk: Overlapping patents may trigger infringement disputes, warranting detailed freedom-to-operate analyses before commercialization.
Summary
JP6798400 covers a specific chemical compound, its use in therapy, formulations, and synthesis methods. The claims are broad but rooted in the chemical structure. The patent landscape shows active filings targeting similar compounds, with competitors employing parallel filings to extend patent life. Challenges include prior art invalidation and scope restrictions, underscoring the importance of continuous patent strategy and legal vigilance.
Key Takeaways
- The patent protects both compound and therapeutic use, with broad claims on salts and formulations.
- Active competition in Japan involves patents on related heterocyclic compounds and kinase inhibitors.
- Patent validity depends on careful management of expiry dates and thorough prior art searches.
- Parallel filings in international markets extend protection but increase legal complexity.
- Ongoing patenting strategies can help sustain market exclusivity beyond initial patent expiry.
FAQs
1. Does JP6798400 cover only the chemical compound, or also its therapeutic uses?
It includes both the compound and methods of use for treating specific diseases.
2. Can a competitor develop a similar compound free of infringement?
If the structure differs significantly or claims are narrowed, it might avoid infringement, but legal analysis is necessary.
3. How many years of exclusivity does JP6798400 likely provide?
Typically, 20 years from the filing date, subject to maintenance fees andextensions.
4. Are there alternative patents that challenge JP6798400's claims?
Yes, prior art references on similar structures or methods could pose challenges.
5. What are the strategies to extend patent protection for products related to JP6798400?
File continuation or divisional patents covering formulations, synthesis, or new indications.
References
[1] Japanese Patent Office. (2022). Patent examination guidelines for pharmaceuticals.
[2] WIPO. (2022). Patent landscape reports for chemical and pharmaceutical patents.
[3] USPTO. (2022). Patent filings related to kinase inhibitors and heterocyclic compounds.
[4] European Patent Office. (2022). Patent applications filed for similar chemical scaffolds worldwide.
Note: This analysis integrates publicly available patent information and industry practices. Specific claims and legal statuses should be verified via official patent databases.
